Search research articles
Contact Us
Filters
Showing results (251-260 of 499) with videos related to
Page
of 50
Sort By:
Plos One
|
November 19, 2013
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer
Salvatore Siena, Eric Van Cutsem, Mingyu Li, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 27, 2014
Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy
Sofie Van Binnebeek, Kristof Baete, Bert Vanbilloen, et al.
ESMO Open
|
June 4, 2020
Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
Jean-Baptiste Bachet, Lucjan Wyrwicz, Timothy Price, et al.
Targeted Oncology
|
August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers
Bernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2023
Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer
Michel Ducreux, Josep Tabernero, Axel Grothey, et al.
Nuklearmedizin. Nuclear Medicine
|
April 9, 2016
Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT
Sofie Van Binnebeek, Michel Koole, Christelle Terwinghe, et al.
Radiology. Imaging Cancer
|
May 27, 2022
Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors
Vincent Vandecaveye, Raphaëla C Dresen, Elin Pauwels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
Eric Van Cutsem, Josep Tabernero, Radek Lakomy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 2004
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
Al B Benson, Deborah Schrag, Mark R Somerfield, et al.
Future Oncology (London, England)
|
May 20, 2025
The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary
Scott Kopetz, Takayuki Yoshino, Eric Van Cutsem, et al.
Page
of 50
Search research articles
Search
Showing results (251-260 of 499) with videos related to
Sort By:
Page
of 50
Plos One
|
November 19, 2013
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer
Salvatore Siena, Eric Van Cutsem, Mingyu Li, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 27, 2014
Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy
Sofie Van Binnebeek, Kristof Baete, Bert Vanbilloen, et al.
ESMO Open
|
June 4, 2020
Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
Jean-Baptiste Bachet, Lucjan Wyrwicz, Timothy Price, et al.
Targeted Oncology
|
August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers
Bernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2023
Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer
Michel Ducreux, Josep Tabernero, Axel Grothey, et al.
Nuklearmedizin. Nuclear Medicine
|
April 9, 2016
Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT
Sofie Van Binnebeek, Michel Koole, Christelle Terwinghe, et al.
Radiology. Imaging Cancer
|
May 27, 2022
Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors
Vincent Vandecaveye, Raphaëla C Dresen, Elin Pauwels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
Eric Van Cutsem, Josep Tabernero, Radek Lakomy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 2004
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
Al B Benson, Deborah Schrag, Mark R Somerfield, et al.
Future Oncology (London, England)
|
May 20, 2025
The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary
Scott Kopetz, Takayuki Yoshino, Eric Van Cutsem, et al.
Page
of 50